Terms: = Pancreatic cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Clinical Outcome
5 results:
1. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract cancer.
Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
[TBL] [Abstract] [Full Text] [Related]
2. Tribody [(her2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract] [Full Text] [Related]
3. Coexpression of EGFR and her-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
Dancer J; Takei H; Ro JY; Lowery-Nordberg M
Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
[TBL] [Abstract] [Full Text] [Related]
4. Osteoclast-like giant cell tumor in mucinous cystadenocarcinoma of the pancreas: an immunohistochemical and molecular analysis.
Sedivy R; Kalipciyan M; Mazal PR; Wolf B; Wrba F; Karner-Hanusch J; Mühlbacher F; Mader RM
Cancer Detect Prev; 2005; 29(1):8-14. PubMed ID: 15734212
[TBL] [Abstract] [Full Text] [Related]
5. Copy number of chromosome 17 but not her2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma.
Stoecklein NH; Luebke AM; Erbersdobler A; Knoefel WT; Schraut W; Verde PE; Stern F; Scheunemann P; Peiper M; Eisenberger CF; Izbicki JR; Klein CA; Hosch SB
J Clin Oncol; 2004 Dec; 22(23):4737-45. PubMed ID: 15570074
[TBL] [Abstract] [Full Text] [Related]